Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

GT Biopharma Promotes COO to Top Post, Effective Immediately

  • Post author:Sam
  • Post published:February 14, 2018
  • Post category:BioPharma

Mr. Cross has held the position of President and COO of GTBP since November 16, 2017. Source: BioSpace

Continue ReadingGT Biopharma Promotes COO to Top Post, Effective Immediately

Guangzhou Facility Warned for Deficient Procedures

  • Post author:Sam
  • Post published:February 14, 2018
  • Post category:Drug Industry Daily

The FDA sent a warning letter to Chinese manufacturer Guangzhou Baiyunshan for failing to follow proper cleaning, validation and storage procedures at its Guangzhou, Guangdong facility. Source: Drug Industry Daily

Continue ReadingGuangzhou Facility Warned for Deficient Procedures

Medtech Petitions FDA for Permission to Change Dosage in ANDA for Generic Excedrin

  • Post author:Sam
  • Post published:February 14, 2018
  • Post category:Drug Industry Daily

Medtech petitioned the FDA to allow the company to submit an ANDA for generic Excedrin in which the proposed product is in a dosage form different from the reference drug.…

Continue ReadingMedtech Petitions FDA for Permission to Change Dosage in ANDA for Generic Excedrin

Cellectis’ T-Cell Gene Editing Technology Granted Patents

  • Post author:Sam
  • Post published:February 14, 2018
  • Post category:Drug Industry Daily

The U.S. Patent and Trademark Office issued two patents to French cell therapy group Cellectis for use of CRISPR technologies in T-cells. Source: Drug Industry Daily

Continue ReadingCellectis’ T-Cell Gene Editing Technology Granted Patents

FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs

  • Post author:Sam
  • Post published:February 14, 2018
  • Post category:Drug Industry Daily

The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily

Continue ReadingFDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs

Azar Defends FY 2019 Budget Request at Congressional Hearing

  • Post author:Sam
  • Post published:February 14, 2018
  • Post category:Drug Industry Daily

In his first appearance as HHS Secretary on Capitol Hill, Alex Azar fielded questions Wednesday about the Trump administration’s plans to address the opioid crisis and drug prices. Source: Drug…

Continue ReadingAzar Defends FY 2019 Budget Request at Congressional Hearing

FDA Declares Pfizer's Atopic Dermatitis Drug a Breakthrough

  • Post author:Sam
  • Post published:February 13, 2018
  • Post category:BioPharma

The Phase 3 program is the first trial in the JAK1 Atopic Dermatitis Efficacy and Safety global development program. Source: BioSpace

Continue ReadingFDA Declares Pfizer's Atopic Dermatitis Drug a Breakthrough

Merck Chemist Arrested for Stealing Deadly Chemical

  • Post author:Sam
  • Post published:February 13, 2018
  • Post category:BioPharma

A 60-year-old chemist has been charged with stealing 219.79 grams of potassium cyanide, a deadly poison, from a Merck facility in Pennsylvania. Source: BioSpace

Continue ReadingMerck Chemist Arrested for Stealing Deadly Chemical

Tetraphase's Lead Antibiotic Fails Another Late-Stage Study

  • Post author:Sam
  • Post published:February 13, 2018
  • Post category:BioPharma

The phase 3 IGNITE3 clinical trial enrolled 1,205 patients who were randomized 1:1 to receive IV eravacycline or ertapenem. Source: BioSpace

Continue ReadingTetraphase's Lead Antibiotic Fails Another Late-Stage Study

3 Biotechs Facing Stiff Headwinds in 2018

  • Post author:Sam
  • Post published:February 13, 2018
  • Post category:BioPharma

The stock market has been rocky recently, but overall the biotech market appears to have been comparatively stable. Source: BioSpace

Continue Reading3 Biotechs Facing Stiff Headwinds in 2018
  • Go to the previous page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 26
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company